Holen Sie sich die Stockscreener-App
59.00
0.15%
0.0516
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Bristol-Myers Squibb Co. (NYSE:BMY): A High-Yield Dividend Stock for Income Investors - ChartMill
Bristol Myers Squibb Company $BMY Shares Sold by Employees Retirement System of Texas - MarketBeat
Colgate-Palmolive Elects Christopher Boerner, Ph.D. to Board of Directors - citybiz
Colgate-Palmolive raises dividend, adds Bristol Myers CEO to board By Investing.com - Investing.com India
Is Bristol Myers' Deep Pipeline the Key to Future Growth? - The Globe and Mail
Piper Sandler Sees Path to Growth for Bristol-Myers Squibb Company (BMY) After Eliquis Patent Expiry - Insider Monkey
UBS Boosts Bristol-Myers Squibb (BMY) Price Target as Milvexian Data Looms - Insider Monkey
BioNTech Stock Tumbles As Co-Founders Pivot To New MRNA Venture - Benzinga
LGT Fund Management Co Ltd. Has $372,000 Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb Readies New Growth Drivers In Immunology And Cancer - simplywall.st
Bristol Myers Squibb (NYSE:BMY) Boosts Research Strengthening S&P 500 Index Momentum - Kalkine Media
Bristol Myers Squibb reports positive phase 3 trial results - Investing.com
Bristol's cancer treatment meets main goal in late-stage trial - AOL.com
Bristol's drug enhances survival rates in late-stage blood cancer trial - Reuters
New Bristol Myers pill delays myeloma progression in key late-stage trial - Stock Titan
Blair William & Co. IL Reduces Bristol Myers Squibb Stake - National Today
Oral Mucositis Market Set to Boom Through 2033 | Bristol-Myers Squibb • Pfizer Inc. • Novartis AG - openPR.com
Pitcairn Co. Sells 20,260 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
B. Metzler seel. Sohn & Co. AG Has $5.05 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers (BMY) Gains FDA Approval for Sotyktu in Psoriatic Arthritis Treatment - GuruFocus
Munich Reinsurance Co Stock Corp in Munich Takes $2.78 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
Grantham Mayo Van Otterloo & Co. LLC Has $43.66 Million Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb's Sotyktu Approved for Psoriatic Arthritis Treatment - Intellectia AI
Bristol Myers Wins FDA Approval for Sotyktu for Psoriatic Arthritis - Benzinga
Bristol Myers wins FDA nod to expand Sotyktu label (BMY:NYSE) - Seeking Alpha
Painful psoriatic arthritis gets new oral option with FDA Sotyktu approval - Stock Titan
UBS raises Bristol-Myers Squibb stock price target on pipeline outlook - Investing.com
Why Bristol-Myers Squibb Remains a Top Healthcare Dividend Stock Pick - Tokenist
IFG Advisory LLC Acquires New Position in Bristol Myers Squibb Company - National Today
Edgar Lomax Co. VA Reduces Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb's Cancer Drug Meets Key Trial Goals - Intellectia AI
Is It Too Late To Consider Bristol Myers Squibb (BMY) After Recent Share Price Strength? - simplywall.st
Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline? - TradingView
Assessing Bristol Myers Squibb (BMY) Valuation After Recent Share Price Momentum And 2024 Results - simplywall.st
Bristol Myers Squibb Awaits FDA Verdict On Sotyktu In Psoriatic Arthritis - RTTNews
Q4 Earnings Outperformers: Bristol-Myers Squibb (NYSE:BMY) And The Rest Of The Branded Pharmaceuticals Stocks - Finviz
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
How New Oncology Wins and a Fresh Dividend At Bristol Myers Squibb (BMY) Have Changed Its Investment Story - simplywall.st
Wealthedge Investment Advisors Boosts Bristol Myers Squibb Holdings - National Today
Bristol Myers Squibb declares $0.63 quarterly dividend - Investing.com
APG Asset Management Trims Bristol Myers Squibb Stake - National Today
Elo Mutual Pension Insurance Co Increases Bristol Myers Squibb Position - National Today
Bristol-Myers Squibb (BMY) Maintains Quarterly Dividend of $0.63/Share - GuruFocus
Bristol Myers Squibb at TD Cowen Conference: Strategic Growth Amid Challenges - Investing.com
BMY Gains 11.4% in a Month: Should You Buy, Sell or Hold the Stock? - TradingView
Evinova and Bristol Myers Squibb Collaborate to Advance AI-Driven Clinical Development - The Healthcare Technology Report.
Elo Mutual Pension Insurance Co Has $13.63 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Co. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
What Bristol-Myers Squibb (BMY)'s Triple-Negative Breast Cancer Phase III Survival Win Means For Shareholders - Yahoo Finance
Bristol-Myers Squibb Cancer Advances Test Valuation Gap For Investors - simplywall.st
Is Bristol Myers Squibb (BMY) Pricing Look Attractive After Recent Share Price Climb - Yahoo Finance
Intech Investment Management Reduces Stake in Bristol Myers Squibb - National Today
Bristol-Myers Campus Sale Suit Sent Back To NJ - Law360
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
US Bancorp DE Trims Bristol Myers Squibb Stake - National Today
Is Bristol-Myers Squibb Stock Underperforming the Nasdaq? - Barchart.com
Mitsubishi UFJ Asset Management Co. Ltd. Has $204.06 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb (NYSE:BMY) Update Pharma Sector Developments - Kalkine Media
Bristol Myers Says New Breast Cancer Drug Shows Survival Benefit In Pretreated Patients - Benzinga
Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer - BioPharma Dive
Bristol Myers: Biokin reports ‘positive’ results from Phase 3 study of iza-bren - TipRanks
Bristol Myers Squibb (BMY) Achieves Breakthrough in Breast Cance - GuruFocus
0.69%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):